• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TRACON Pharmaceuticals, Inc. - Common Stock (NQ:TCON)

1.430 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TRACON Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
TRACON Pharmaceuticals Announces it Will Wind Down Operations
July 30, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
July 01, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
June 11, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 07, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Reverse Stock Split
April 08, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
April 03, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
March 05, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
February 28, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
December 20, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
November 20, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
October 31, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
September 18, 2023
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
September 05, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
August 02, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
July 11, 2023
Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of the ENVASARC Pivotal Trial 
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
June 20, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
June 16, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
June 15, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
May 30, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
May 03, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
April 25, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update
April 06, 2023
From Runway Growth Finance Corp.
Via GlobeNewswire
News headline image
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 08, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
February 28, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update
January 10, 2023
From Runway Growth Finance Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap